<DOC>
	<DOCNO>NCT00005594</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness ISIS 2503 treat patient advanced cancer pancreas .</brief_summary>
	<brief_title>ISIS 2503 Treating Patients With Advanced Cancer Pancreas</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate time progression patient advance adenocarcinoma pancreas treat ISIS 2503 . II . Determine duration response patient receive regimen . III . Characterize safety profile ISIS 2503 recommend phase II dose schedule patient . OUTLINE : Patients receive ISIS 2503 IV continuously 14 day . Treatment continue every 21 day minimum 3 course absence unacceptable toxicity disease progression . PROJECTED ACCRUAL : A total 14-27 patient accrue study within 12 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced adenocarcinoma pancreas consider inoperable Measurable disease least 1 lesion measure least 2 cm wide diameter identifiable CT MRI scan PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 2.0 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 6 month study No underlie disease state associate active bleeding No active infection require therapy No prior malignancy within past 5 year except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy pancreatic cancer Chemotherapy : No prior chemotherapy pancreatic cancer except fluorouracil and/or gemcitabine administer radiosensitizer No concurrent chemotherapy pancreatic cancer Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow provided indicator lesion within prior radiation port Recovered toxicity No concurrent radiotherapy pancreatic cancer Surgery : See Disease Characteristics Other : No concurrent anticoagulation therapy heparin No concurrent approve experimental cancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>